Cara Therapeutics shares are trading higher by 15% during Thursday's session. The company earlier announced it engaged Piper Sandler & Co. as a financial advisor to explore strategic alternatives. See ...

Cara Therapeutics (NASDAQ:CARA) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of ...

Cara Therapeutics (NASDAQ: CARA) shareholders breathed sighs of relief following the recent Kalm-1 trial readout. The first of two pivotal studies produced results that sent the stock soaring, and ...

Cara Therapeutics Inc (CARA) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 14, 2024 for Q3. Cara Therapeutics Inc (CARA) does not ...

H.C. Wainwright analyst Oren Livnat maintained a Buy rating on Cara Therapeutics (CARA – Research Report) today and set a price target of $2.50. Oren Livnat has given his Buy rating due to a ...

CR845, a novel, peripherally restricted kappa opioid agonist, is currently in Phase 2 development for treatment of post-operative pain SHELTON, Conn., July 21 /PRNewswire/ -- Cara Therapeutics, Inc.

The biotech's financial performance in Q3 really doesn't matter. But its pipeline progress for Korsuva does. Cara Therapeutics announced its third-quarter results after the market closed on Tuesday.

Stamford-based Cara Therapeutics Inc. announced Monday that its board of directors has approved a 1-for-3 reverse common stock stock split. Cara’s common stock, which trades on the Nasdaq stock ...

The morbid reality of the opioid epidemic is all around us. About 30,000 people die in the U.S. each year from overdoses involving opioids; that's 82 people a day, according to the Centers for Disease ...

It's been a very good week for Cara Therapeutics, Inc. (NASDAQ: CARA). The biotech stock soared after Cara reported positive results from a phase 2/3 clinical study of intravenous (IV) CR845 in ...

What should investors think of this promising biotech stock and its pruritus drug candidate? While the company reported its Q3 earnings a couple of weeks ago, the main driver for Cara Therapeutics' ...